FDA Is Said to See "Path Forward" for Ecstasy-based Drug
Express News | Compass Pathways PLC in Addition, Selling Security Holders Offering up to 9.45 Mln Ordinary Shares - SEC Filing
Buy Rating Affirmed for COMPASS Pathways Amid Promising Psilocybin Treatment Prospects and Strategic Market Positioning
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
RBC Capital analyst Leonid Timashev maintains $COMPASS Pathways(CMPS.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 44.3%
RBC Capital Remains a Buy on COMPASS Pathways (CMPS)
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Compass Therapeutics Files $300M Mixed Securities Shelf
Compass Pathways to Participate in Three Investor Conferences in September
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Trials for Psychedelic Drug Candidate for PTSD Under Scrutiny by FDA - Report
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Buy Rating Affirmed for COMPASS Pathways Amid Progress in Pivotal Trials and Strong Financial Position
CCORF Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $48
CCORF analyst Sumant Kulkarni maintains $COMPASS Pathways(CMPS.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 42.7% and a
Buy Rating Affirmed: COMPASS Pathways' Promising Clinical Trials Advance Psychedelic Therapeutics
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
Lykos Therapeutics to Cut About 75% of Workforce -- Update
TD Cowen Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
TD Cowen analyst Ritu Baral maintains $COMPASS Pathways(CMPS.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 45.2% and a
TD Cowen Remains a Buy on COMPASS Pathways (CMPS)